In an interview with ET Now, Sarabjit Kour Nangra from Angel Broking expresses her outlook on lower revenue trends indicated by Tech Mahindra and other IT organizations. ET Now: Tech Mahindra has come out with its report, they are saying that the ... Economic Times, 2 days ago
TechM projects tepid Q1 revenues, stock dives 7% - The Financial Chronicle, 2 days ago
1 images for "sarabjit kour nangra"
T Below is the transcript of Sarabjit Kour Nangra's & Ajay Bagga's interview with Latha Venkatesh & Ekta Batra on CNBC-TV18. Latha: Did you get to read the New York Times article and the flashes that we ran, is this going to be a major negative ...Moneycontrol.com, 2 weeks ago Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel Broking Economic Times, 1 month ago Ranbaxy effect playing on Sun Pharma's margins: Pros Money Control, 1 month ago HCL Tech shares tank nearly 10% as Q3 earnings disappoint DNA, 2 months ago
They have been guiding again and again that FY17 onwards, they expect Infosys to be back being the bellwether company in terms of the IT sector. In an interview with ET Now, Sarabjit Kour Nangra, VP - Research, Angel Broking, shares her views on the Infosys ...Economic Times, 2 months ago
A year after the last recall of its generic hypertension drug Metroprolol, Hyderabad-based Dr Reddy's Laboratories Limited has initiated a nationwide voluntary recall of two more drugs earlier this month -Divalproex Sodium extended release tablets ...Business Standard India, 2 days ago
AHMEDABAD: Leading drug makers from the state are turning to plant extracts. Gujarat based companies, primarily engaged into manufacturing of drugs, are now focusing on over-the-counter (OTC) herbal products. Pankaj Patel promoted Zydus Cadila, ...Times of India, 5 days ago
Mumbai: Drugmaker Lupin on Tuesday said its Board of directors has given an in-principle approval for raising up to Rs 7,500 crore. The company is looking at some big-ticket acquisitions and may utilise the funds for the purpose, industry experts ...Pharmacy Choice, 6 days ago Lupin readies Rs 7,500 crore war chest DNA India, 1 week ago Lupin to raise Rs 7,500 cr, sets off acquisition buzz on D-St. Financial Chronicle, 1 week ago
MUMBAI: Shares of AstraZeneca have broken out of the narrow trading range in June, driven by two positive news flows. The stock has rallied 37.41 per cent since June 3. It surged 9.5 per cent intraday today and given the buying momentum, it can ...Economic Times, 1 week ago
BT Online Bureau New Delhi Last Updated: June 22, 2015 | 00:00 IST Aurobindo Pharma shares were trading higher on the bourses on Monday after it announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and ...Money Today, 1 week ago
Washington/Bengaluru, June 12 The US has opened an investigation into two top Indian IT companies -- Tata Consultancy Services and Infosys -- for possible violations of rules for H-1B visas for foreign technology workers, according to a media ...ProKerala.com, 2 weeks ago
More from: , New Indian Express...and 6 other sources
Bengaluru, June 12 The US government is learnt to have begun investigating alleged H1-B visa violations by Indian software majors Tata Consultancy Services (TCS) and Infosys Ltd, according to a US media report. The US labor department has ...ProKerala.com, 2 weeks ago Angel Broking maintains 'Buy' on Infosys, TCS MyIris, 2 weeks ago 'US begins probe into alleged visa violation by TCS, Infosys' Daijiworldcom, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!